5 Reasons to

Upgrade to LCDB Plus

LCDB Plus encompasses 127% more carcinogenicity data, to support you in demonstrating robust assessment. More data, on more compounds, giving you more compound-specific assessments!

Innovative functionality allows you to perform TD₅₀ calculations for your own carcinogenicity datasets using regulatory-aligned TD₅₀ methodology from Lhasa.

LCDB Plus features enhanced Lhasa Reliability Scoring, efficient for ICH M7 Class 1 impurities, and pinpointing those studies most suitable for dose-response modelling with a new A+ reliability grade.

Selecting between studies of comparable reliability can be challenging; LCDB Plus flags sensitive sites and the most robust study, allowing rapid identification of the “most sensitive site in the most robust study”.

LCDB Plus provides the toolkit for carcinogenicity knowledge and decision-support, strengthening Weight of Evidence (WoE) assessments and Context of Use in NAMs-based regulatory submissions.

The tool is specifically designed by Scientists to prioritise the delivery of the most relevant data, to accelerate expert review and scientific justifications.

Complete your workflow:

Upgrade access:

Get in touch below to secure your license for LCDB Plus!

Explore our related solutions that can help you transform the carcinogenic potency dataset into a complete in silico carcinogenicity risk assessment workflow: Derek, Sarah, Vitic and Acrostic.

Explore LCDB Plus in-platform:

Preview the features of LCDB Plus with our interface demo below.

5 Reasons to

Upgrade to LCDB Plus

Complete your workflow:

Upgrade access:

Explore LCDB Plus in-platform:

Sign up to our newsletter

Connect with us